## AMGN: Amgen Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.02 indicates fundamental undervaluation. Quality metrics strong (ROE 82%). Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($317.35)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Amgen Stock After Hours (AMGN) on Dec. 22, 2025: FDA Clears New Prolia/Xgeva Biosimilars, Fitch Upgrades Credit — What to Know Before the Dec. 23 Open**
- Source: ts2.tech | 20251223T010708 | Neutral | Relevance: 100%
- Amgen (NASDAQ: AMGN) faces opposing forces before the December 23rd market open: the FDA approved new biosimilars for its blockbuster drugs, Prolia and XGEVA, which could increase competitive pressure. However, Fitch upgraded Amgen's credit rating to BBB+, signaling improved financial flexibility and a positive counterweight to biosimilar concerns. Investors will weigh these factors along with ongoing drug-pricing policy discussions and the impact of holiday-week liquidity.

**2. Amgen Stock (AMGN) News Today: Trump Drug‑Price Deals, Analyst Forecasts, and What to Watch Next — Dec. 22, 2025**
- Source: ts2.tech | 20251222T180808 | Somewhat-Bullish | Relevance: 100%
- Amgen Inc. (NASDAQ: AMGN) is currently under investor scrutiny due to new White House drug-pricing agreements, notably a "most-favored-nation" (MFN) push, and potential impacts on 2026 earnings. Analysts suggest these deals might be more about political and tariff uncertainty reduction than immediate profit compression. The stock traded higher despite these developments, driven by strong Q3 2025 earnings and promising pipeline developments in obesity and oncology, though MFN policies and pipeline risks remain key considerations for investors.

**3. Sarasin & Partners LLP Buys 47,873 Shares of Amgen Inc. $AMGN**
- Source: MarketBeat | 20251221T130935 | Bullish | Relevance: 100%
- Sarasin & Partners LLP increased its stake in Amgen Inc. by 7.8% in Q3, purchasing 47,873 shares to reach a total of 659,993 shares, valued at $180.82 million. This makes Amgen its 24th largest holding, representing about 1.8% of its portfolio. Amgen recently reported strong earnings, beating analyst expectations, and increased its quarterly dividend to $2.52 per share, resulting in a 3.1% yield.

**4. Amgen Stock (AMGN) News Today: TrumpRx Drug-Price Deal, FDA Approvals, Dividend Update, and 2026 Analyst Forecasts**
- Source: ts2.tech | 20251220T171830 | Somewhat-Bullish | Relevance: 100%
- Amgen Inc. (NASDAQ: AMGN) is navigating a complex landscape of policy changes, including a new drug-pricing deal with the Trump administration that offers pricing concessions for tariff relief. The company has also received significant FDA approvals for UPLIZNA and IMDELLTRA, strengthening its growth prospects and pipeline, while reaffirming its dividend for Q1 2026. Analysts present a split outlook for Amgen's stock in 2026, reflecting both pipeline potential and ongoing policy risks.

**5. Amgen’s Long-Term Pediatric Psoriasis Study on Apremilast: Why the Latest Update Matters for Investors**
- Source: TipRanks | 20251222T163506 | Somewhat-Bullish | Relevance: 100%
- Amgen (AMGN) has provided an update on its long-term Phase 3b clinical study of apremilast for pediatric plaque psoriasis, which aims to assess its long-term safety and efficacy in children aged 6 to 17. The study's status is now listed as completed, though data cleaning and reporting are reportedly ongoing, with no public results yet available. A positive outcome could bolster apremilast's market position against competitors like Novartis and Eli Lilly, supporting label expansion and investor confidence in the drug's long-term value within Amgen's inflammation portfolio.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Morgan Stanley | $304 | $329 | -8% |
| 2025-12-10 | Wells Fargo | $325 | $300 | +8% |
| 2025-12-03 | BMO Capital | $372 | $335 | +11% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Morgan Stanley | main | Equal-Weight |
| 2025-12-10 | Wells Fargo | main | Equal-Weight |
| 2025-12-03 | BMO Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($0.00M) |
| Sells | 7 ($2.74M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (+0.3%)
- Blackrock Inc.: 8.6% (-1.2%)
- State Street Corpora: 5.4% (-0.2%)
- Capital Internationa: 3.6% (+1.5%)
- Capital World Invest: 3.5% (+11.5%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.02 suggests fair value with growth premium. Forward P/E 15.1x stretched relative to 3% growth. Quality metrics strong (ROE 82%, margin 20%). Balance sheet: $4.2B free cash flow. Analyst sentiment positive (2 raises, avg +10%). Insider selling cluster ($2.7M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $178.4B |
| Beta | 0.45 |
| 52W Range | $257.05 - $346.38 |
| Short Interest | 2.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.02 |
| Forward P/E | 15.1 |
| Current P/E | 15.6 |
| YoY Growth | 3.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -1.6% to -0.2% (+1.4% in 5 days), confirming momentum buildup. Below STRENGTH zone by 4.2pp (needs >4.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-0.82), momentum weakening. RSI neutral at 56. Elevated volume (1.9x 20MA), institutional activity likely. OFD pattern: +MTL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.23% (CS: 44) | Neutral |
| RSI_14 | 55.5 | Neutral |
| MACD Histogram | -0.82 | Bearish |
| vs SMA20 | 1.004x | Above |
| vs SMA50 | 1.039x | Above |
| vs SMA200 | 1.115x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $331.39
- **Stop Loss:** $317.35 (4.2% risk)
- **Target:** $359.47 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 85
- **Position Value:** $28,168.15
- **Portfolio %:** 28.17%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-02-03 (Est: $4.74)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.01 | $5.64 | +12.5% |
| 2025Q2 | $5.28 | $6.02 | +14.1% |
| 2025Q1 | $4.26 | $4.90 | +15.0% |
| 2024Q4 | $5.08 | $5.31 | +4.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*